BLRX BioLineRx, Ltd.

$BLRX In the next day or 2 H.C. Wainwright will value Blrx above 20 dollars. This is the same playbook phil uses when he is slowly putting the knife in investors backs. You can bet the offering is helping one or two of his hedge fund Buddies. Phil talks about a collaboration with another firm. Every collaboration he has made has helped him and the board, not investors. Remember Phil is a liar and a thief.

$BLRX Continues to slowly decline onto the abyss where it belongs. this is a trash stock.

$BLRX Phil just covered his pay for the next 3 years....remember Phil is a liar and a thief

$BLRX targeted a $3.75 million registered direct offering of 480,696 ADSs and related warrants, closing expected end of August.

$BLRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $0.29M down -3.33% YoY • BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.

$BLRX BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.prnewswire.com/news-releases/biolinerx-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302864836.html • $13.1M cash as of June 30, runway into 1H 2027. • Aphexda royalty revenue $304K, from sales of $1.6M by Ayrmid last quarter. Lower than Q1 - $477K in royalty revenue from $2.7M in sales. • Net loss last qtr $4.339M. • CheMo4METPANC futility analysis still on track for 2026. • GLIX1 clinical and pre-clinical data have been accepted for publication at the EANO Conference in Sept 2026 and at the SNO Annual Meeting in Nov 2026. • GLIX1 Ph1/2b trial, 2nd of five planned cohorts ongoing in GBM; third patient cohort expected to commence dosing in September.

$BLRX started to build my position back up a bit recently, but after yesterdays update to their trial, i sold. not expecting good news there. hopefully can get a good glix update but man... this stock and company suck

$BLRX BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement https://www.prnewswire.com/news-releases/biolinerx-announces-3-75-million-registered-direct-offering-and-concurrent-private-placement-302862746.html • 1,348,921 ADS at a purchase price of $2.78, in a registered direct offering. • Warrants to purchase 2,023,382 ADS with a $2.78 exercise price, in a concurrent private placement. • They also entered into a warrant amendment with the investor in the offering. Warrants to purchase 277,273 ADSs that were previously issued in other offerings were reduced to $2.78 and now expire Aug 2031. • Closing expected Aug 31. Aggregate gross proceeds are expected to be $3.75 million.

$BLRX set its second-quarter 2026 results release for Aug. 31, with a pre-market conference call at 8:30 a.m. EDT.